Record First Quarter and Sustained Multi-year Growth Trend
Simulations Plus Reports FY2010 and Fourth Quarter FY2010 Financial Results
Fiscal Year Earnings Jump 52.7% on 17.2% Revenue Increase
Simulations Plus Sets Date for 4 th Quarter and Fiscal Year 2010 Earnings Release and Conference Call
Conference Call to be on Tuesday, November 30, at 4:15 PM EST
Learning to be an architect of ideas.
I have long been addicted to The New York Times Book Review. It is not that I am a writer groupie as much as I find it fascinating to read about how a book came about.
Development of A Mechanistic in vitro – in vivo Correlation for Theophylline
Theophylline is used to prevent and treat wheezing, shortness of breath, and difficulty breathing caused by asthma, chronic bronchitis, emphesema, and other lung diseases. Immediate release oral…
Application of a Respiratory PBPK Model for Predicting Deposition and Disposition following Inhaled Administration of Morphine
Demonstrate the pulmonary component of the GastroPlus™ Additional Dosage Routes Module™ (ADRM) simulation to develop a pharmacokinetic (PK) and pharmacodynamic (PD) model for inhaled…
Mechanistic PBPK Simulation in Place of In Vivo Drug-Drug Interaction (DDI) Studies for Compliance with Regulatory Requirements of EMA and FDA
To highlight the application and validation of PBPK DDI simulation results obtained using GastroPlus™ in compliance with newly proposed European Medicines Agency (EMA) and US FDA guidelines for the…
You WILL Innovate!
Few among us would think highly of a leader who directed us to innovate on demand. After all, innovation is something that comes from a mysterious creative force that strikes like lightning to the fortunate inventor, bringing with it fame and fortune. Think Bill Hewlett and Dave Packard; Steve Jobs and Steve Wozniak; Bill Gates; Mark Zuckerberg; or Tim Berners-Lee (huh?) [1].
Bendamustine pharmacokinetic profile and exposure-response relationships in patients with indolent non-Hodgkin’s lymphoma
The pharmacokinetic profiles of bendamustine and active metabolites were defined in patients with rituximab-refractory, relapsed indolent B-cell non-Hodgkin's lymphoma, and supported understanding of exposure-response relationships for efficacy and safety.
Dissolution modeling of bead formulations and predictions of bioequivalence for a highly soluble, highly permeable drug
The objective of this study was to assess the impact of observed in vitro dissolution rate differences on in vivo pharmacokinetics for two enteric-coated bead formulations...
Model hurricanes.
Although some meteorological modelers may disagree, it seems to me that models predicting development and movement of hurricanes are getting more and more accurate.
But…my projects are special.
Scientists in the field of pharmaceutical research and development face a most daunting challenge. Our understanding of the diseases we work to treat grows more complex and perplexing with each new published study. Take, for example, the gusher of information coming out on Alzheimer’s disease. How can research findings from genetics, neurology, nutrition, protein chemistry, pharmacology, and epidemiology (just to name a few) be tracked, sorted, and used?
Simulations Plus to Present at the Rodman & Renshaw Annual Global Investment Conference
Leading Provider of Simulation and Modeling Software for Pharmaceutical Discovery and Development Scheduled to Present on September 13, 2010; Rodman & Renshaw Annual Global Investment Conference NYC
What if the constants we take for granted are not really constant?
Seems like every time we learn something new, whether it is in biology or cosmology, we learn something else that just makes us sit back and say Wow. So it is with a recent story in The Economist about new information regarding one of the universal “constants” alpha.
Simulations Plus Reports Preliminary Revenues for Fourth Fiscal Quarter of FY2010
New Record Fiscal Year Follows Record 1st, 2nd and 3rd Quarters; Rodman & Renshaw Annual Global Investment Conference NYC
Beyond Filters: ADMET Risk™ for Multi-objective Drug Development
We calculated predictions for over 30 properties relevant to absorption, distribution, metabolism, excretion and toxicity (ADMET) for a large and pharmaceutically pertinent...
Kinda like standing in front of a development team, huh?
G.H. Hardy* said, “A mathematician, like a painter or a poet, is a maker of patterns. And just as in poetry and painting, the mathematician’s patterns must be beautiful. Beauty is the first test,” he said. “There is no permanent place in the world for ugly mathematics.”
Not too complicated for words.
Jackson Pollock’s Autumn Rhythm (seen here) is an example of a complex painting that can be grasped with a few moments of contemplation, according to Terry Teachout (links to a dead page) in the Wall Street Journal. Pollock worked during the mid 20th century, when nature was assumed to be random. However, as Robert Taylor (links to content that is no longer available) explained in a 2002 Scientific American article: